SCHEMBL2467646

SCHEMBL2467646

Cc1c(O)cccc1C(=O)NN

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 2/20 0.56
MAPT P10636 3/20 0.49
CTSD P07339 2/20 0.49
GAA P10253 2/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
CA9 Q16790 1/20 0.49
MITF O75030 1/20 0.49
NCOA1 Q15788 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
NCOA3 Q9Y6Q9 1/20 0.49
ALDH1A1 P00352 5/20 0.47
GFER P55789 1/20 0.47
LMNA P02545 3/20 0.46
HTT P42858 3/20 0.46
HSD17B10 Q99714 3/20 0.46
NPC1 O15118 3/20 0.46
RAB9A P51151 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14164188 0.82 PLK1 (0.52) MAPTGAAMEN1KMT2ACA1
SCHEMBL668153 0.82 P2RX7 (0.53) P2RX7MAPTCTSDMEN1KMT2A
SCHEMBL32018464 0.82 TERT (0.61) P2RX7MAPTCTSDGAAMEN1
SCHEMBL723254 0.82 TERT (0.61) P2RX7MAPTCTSDGAAMEN1
SCHEMBL12677093 0.81 CA1 (0.50) MAPTMEN1KMT2ACA1CA2
SCHEMBL18010449 0.79 KDM4E (0.65) MAPTCTSDGAAMEN1KMT2A
SCHEMBL161525 0.79 KDM4E (0.65) MAPTCTSDGAAMEN1KMT2A
SCHEMBL30489955 0.79 KDM4E (0.65) MAPTCTSDGAAMEN1KMT2A
SCHEMBL17063932 0.79 P2RX7 (0.50) P2RX7MAPTCTSDGAAMEN1
SCHEMBL16054667 0.79 TAS1R3 (0.52) P2RX7MAPTCTSDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2550266-B1 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION AMITECH THERAPEUTICS SOLUTIONS INC (US) 2018-05-09 EP disclosed
US-20160096824-A1 Heterocyclic Compounds Useful for Kinase Inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. 2016-04-07 US disclosed
US-9212151-B2 Heterocyclic compounds useful for kinase inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. (US) 2015-12-15 US disclosed
US-20150158828-A1 Heterocyclic Compounds Useful for Kinase Inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. 2015-06-11 US disclosed
US-8957216-B2 Heterocyclic compounds useful for kinase inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. (US) 2015-02-17 US disclosed
US-20130123284-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION AMITECH THERAPEUTIC SOLUTIONS INC (US) 2013-05-16 US disclosed
EP-2550266-A2 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION Amitech Therapeutics Solutions, Inc. (US) 2013-01-30 EP disclosed
WO-2011119894-A2 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION KINAGEN, INC (US) 2011-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123284-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION MAP4K2, MAP3K20, MAP3K19 P2RX7 4043/4885MAPT 4114/4885CTSD 3706/4885
US-20150158828-A1 Heterocyclic Compounds Useful for Kinase Inhibition MAP4K2, MAP3K20, MAP3K19 P2RX7 4043/4885MAPT 4114/4885CTSD 3706/4885
US-20160096824-A1 Heterocyclic Compounds Useful for Kinase Inhibition MAP4K2, MAP3K20, MAP3K19 P2RX7 4043/4885MAPT 4114/4885CTSD 3706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.